Shareprice
03 Jun 2026

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

Invitation to brain surgery simulation

News


May 13, 2026

Copenhagen, Denmark, 13 May 2026 – FluoGuide A/S ("FluoGuide" or the "Company") is inviting investors to an event on Tuesday, June 2, 2026, where participants will get a close-up look at the company’s technology and clinical applications through a live brain surgery simulation using FluoGuide’s drug candidate FG001.

The attendees will have the opportunity to

  • Do a live microscope-based simulation of brain surgery and experience the difference between surgery performed with and without FG001.
  • Meet Dr Jane Skjøth-Rasmussen, MD, PhD. neurosurgeon at Rigshospitalet, who leads the Danish clinical trials in brain tumors with FG001 and has performed the highest number of surgeries using FG001 to date.
  • Learn about the practical implications of FluoGuide’s: FDA Fast Track designation and IND (Investigational New Drug) clearance for the U.S. market.
  • Gain insight into the clinical results for FG001 and upcoming milestones in aggressive brain cancer and head & neck cancer.

Time and Location

  • Date: Tuesday, June 2, 2026
  • Time: 16:30–18:00 CET
  • Location: Titanhus, Titangade 9–13, 2200 Copenhagen.

The invitation (in Danish is enclosed). Registration is required by follow this link (https://fluoguide.com/event/fluoguide-event/)